PepCalcs
    Back to Library

    SS-31

    Phase 2 TrialsReached Phase 3 trials for primary mitochondrial myopathy. The sponsor's program was disrupted by financial challenges.

    SS-31 (Elamipretide)

    Description

    A mitochondria-targeting antioxidant peptide that protects against oxidative stress. Studied for age-related diseases and cellular energy.

    Dose:500 mcg
    Frequency:5 days on, 2 days off (8 weeks on/off cycle)
    Administration Method: SQ, IV
    CategoryLongevity
    Half-LifeApproximately 2-5 hours (subcutaneous).

    Overview

    SS-31 (elamipretide) is a synthetic tetrapeptide developed by Drs. Hazel Szeto and Peter Schiller. It has been studied for cardiac mitochondrial dysfunction, ischemia-reperfusion injury, primary mitochondrial myopathy, and age-related mitochondrial decline.

    Mechanism of Action

    SS-31 (elamipretide) targets the inner mitochondrial membrane and interacts with cardiolipin, stabilizing the respiratory chain and improving mitochondrial bioenergetics.

    Benefits

    • •Mitochondrial protection
    • •Antioxidant
    • •Cellular energy
    • •Heart health
    • •Age-related disease
    • •Muscle function

    Dosing Notes

    Preclinical mouse studies of cisplatin-induced acute kidney injury used 10 mg/kg/day for 10 days.

    Reported Side Effects

    • •Injection site reactions
    • •Headache
    • •Limited long-term human data

    Scientific References

    Related Longevity Peptides